What is tremfya?

What is tremfya?

Tremfya is a prescription biologic used to treat plaque psoriasis and psoriatic arthritis. It contains guselkumab, an interleukin-23 inhibitor that targets the root cause of inflammation in these conditions.

Why do patients choose Tremfya over other biologics?

Patients select Tremfya for its convenient dosing schedule. After two starter doses four weeks apart, maintenance injections occur every eight weeks. Many people report cleaner skin and less joint pain compared to oral medications or frequent injections.

What happens if you miss a dose of Tremfya?

If you miss a dose, inject it as soon as you remember. Then resume your regular every-eight-week schedule from the date of that missed dose. Consult your doctor if you have more than two weeks time difference from your regular schedule.

How does Tremfya compare with Skyrizi?

Tremfya and Skyrizi are both IL-23 inhibitors. They share similar efficacy and dosing patterns. Tremfya is approved for psoriatic arthritis in addition to plaque psoriasis, while Skyrizi has approval for Crohn's disease. The companies behind them differ—Tremfya is made by Janssen, Skyrizi by AbbVie.

When does Tremfya's patent expire?

Tremfya's primary composition-of-matter patent expires in 2031. Biosimilars may enter the market around then oder shortly thereafter. DrugPatentWatch.com reports current patent and exclusivity timelines for Tremfya.